Lambert-Eaton syndrome involves autoimmune attack on which presynaptic structure?

Prepare for the Clinical Connections Test. Utilize flashcards and multiple choice questions, each with hints and explanations. Excel in your exam!

Multiple Choice

Lambert-Eaton syndrome involves autoimmune attack on which presynaptic structure?

Explanation:
Lambert-Eaton myasthenic syndrome is caused by autoantibodies that attack the presynaptic voltage-gated calcium channels at the neuromuscular junction. These channels normally open to allow calcium influx when a nerve impulse arrives, which triggers acetylcholine-containing vesicles to fuse with the presynaptic membrane and release ACh into the synaptic cleft. When these calcium channels are blocked, less acetylcholine is released, so the postsynaptic muscle receptors aren’t sufficiently stimulated, leading to weakness and autonomic symptoms. This is different from attacks on acetylcholine receptors, which occur in myasthenia gravis and are postsynaptic. Dopamine receptors are CNS targets and not part of NMJ transmission, and sodium channels in the axon hillock are involved in initiating the action potential, not in triggering acetylcholine release at the NMJ.

Lambert-Eaton myasthenic syndrome is caused by autoantibodies that attack the presynaptic voltage-gated calcium channels at the neuromuscular junction. These channels normally open to allow calcium influx when a nerve impulse arrives, which triggers acetylcholine-containing vesicles to fuse with the presynaptic membrane and release ACh into the synaptic cleft. When these calcium channels are blocked, less acetylcholine is released, so the postsynaptic muscle receptors aren’t sufficiently stimulated, leading to weakness and autonomic symptoms.

This is different from attacks on acetylcholine receptors, which occur in myasthenia gravis and are postsynaptic. Dopamine receptors are CNS targets and not part of NMJ transmission, and sodium channels in the axon hillock are involved in initiating the action potential, not in triggering acetylcholine release at the NMJ.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy